Verrica Pharmaceuticals Inc. Quarterly Nonoperating Income (Expense) in USD from Q3 2017 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Verrica Pharmaceuticals Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q3 2017 to Q2 2024.
  • Verrica Pharmaceuticals Inc. Nonoperating Income (Expense) for the quarter ending June 30, 2024 was -$1.98M, a 416% decline year-over-year.
  • Verrica Pharmaceuticals Inc. Nonoperating Income (Expense) for the twelve months ending June 30, 2024 was -$6.07M, a 14562% decline year-over-year.
  • Verrica Pharmaceuticals Inc. annual Nonoperating Income (Expense) for 2023 was -$1.24M, a 61.3% increase from 2022.
  • Verrica Pharmaceuticals Inc. annual Nonoperating Income (Expense) for 2022 was -$3.19M, a 23.5% increase from 2021.
  • Verrica Pharmaceuticals Inc. annual Nonoperating Income (Expense) for 2021 was -$4.17M, a 66% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$6.07M -$1.98M -$2.61M -416% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$3.47M -$1.73M -$2.23M -446% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 -$1.24M -$1.48M -$1.76M -626% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-29
Q3 2023 $522K -$885K +$480K +35.2% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $42K $626K +$1.67M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$1.63M $500K +$1.56M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 -$3.19M $281K +$1.35M Oct 1, 2022 Dec 31, 2022 10-K 2024-02-29
Q3 2022 -$4.54M -$1.37M -$304K -28.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$4.24M -$1.05M -$3K -0.29% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$4.24M -$1.06M -$64K -6.43% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 -$4.17M -$1.07M -$127K -13.5% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-06
Q3 2021 -$4.05M -$1.06M -$212K -25% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 -$3.83M -$1.04M -$266K -34.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$3.57M -$996K -$1.05M -1817% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 -$2.51M -$944K -$1.3M -367% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-02
Q3 2020 -$1.22M -$849K -$1.3M -287% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 $86K -$778K -$1.3M -250% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 $1.38M $58K -$489K -89.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q4 2019 $1.87M $353K -$257K -42.1% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-13
Q3 2019 $2.13M $453K +$27K +6.34% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $2.1M $520K +$367K +240% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 $1.74M $547K +$506K +1234% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $1.23M $610K +$1.61M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-13
Q3 2018 -$380K $426K +$1.43M Jul 1, 2018 Sep 30, 2018 10-K 2020-03-13
Q2 2018 -$1.81M $153K Apr 1, 2018 Jun 30, 2018 10-K 2020-03-13
Q1 2018 $41K Jan 1, 2018 Mar 31, 2018 10-K 2020-03-13
Q4 2017 -$1M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-07
Q3 2017 -$1M Jul 1, 2017 Sep 30, 2017 10-K 2019-03-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.